{
  "outcomes_metadata": {
    "timestamp": "2025-10-04T14:05:36.763482",
    "indication": "treatment of patients with advanced or unresectable hepatocellular carcinoma",
    "consolidation_type": "outcomes",
    "data_split": "test",
    "total_unique_outcomes": 134,
    "source_countries": [
      "AT",
      "BE",
      "CZ",
      "DE",
      "DK",
      "EN",
      "ES",
      "EU",
      "FR",
      "IT",
      "NL",
      "PO",
      "PT",
      "SE"
    ],
    "source_types": [
      "clinical_guideline",
      "hta_submission"
    ]
  },
  "consolidated_outcomes": {
    "efficacy": {
      "survival_endpoints": [
        "overall survival (OS)",
        "all-cause mortality",
        "mortality",
        "long-term survival",
        "5-year survival",
        "median survival",
        "improved survival",
        "progression-free survival (PFS)",
        "progression-free survival (PFS; RECIST 1.1)",
        "progression-free survival (modified RECIST)",
        "progression-free survivorship",
        "time to progression (TTP)",
        "time to progression",
        "time to progression of the tumor",
        "time-to-progression",
        "time to radiological disease progression",
        "time to symptomatic progression (TTSP)",
        "time to symptomatic disease progression (FHSI-8 questionnaire)",
        "time to symptom progression",
        "time to deterioration",
        "time to patient-reported impairment of quality of life (EORTC QLQ-C30)",
        "time to patient-reported impairment of quality of life (EORTC QLQ-HCC18)",
        "time to clinically meaningful worsening of EQ-5D",
        "time to clinically meaningful worsening of EORTC QLQ-C30 domains",
        "time to clinically meaningful worsening of EORTC QLQ-HCC18 domains",
        "disease recurrence",
        "recurrence",
        "delay of recurrence",
        "early detection of recurrence",
        "local control",
        "local tumour control",
        "success rate (downstaging/bridging)",
        "bridging therapy benefit (time to progression)"
      ],
      "response_measures": [
        "objective response rate (ORR)",
        "objective response rate (ORR; RECIST 1.1)",
        "objective response rate (ORR; mRECIST)",
        "tumor response rate",
        "tumour response rate",
        "response rates",
        "response rates (RECIST criteria)",
        "response rates (mRECIST)",
        "response rates (RECIS systems)",
        "response rates (multiphase computed tomography with contrast)",
        "response rates (magnetic resonance imaging with contrast)",
        "partial response (PR)",
        "partial response",
        "minor response (reduction of tumour size by 25 to 50%)",
        "complete response (CR)",
        "complete remission",
        "objective tumour response",
        "stable disease (SD)",
        "stable disease (for at least 16 weeks)",
        "disease control rate (DCR)",
        "disease control rate (DCR; mRECIST)",
        "disease control",
        "clinical benefit rate (CBR)",
        "tumor reduction",
        "tumor burden",
        "time to response",
        "duration of response (DoR)",
        "duration of response (DoR; time from partial or complete response to disease progression or exit)",
        "effectiveness of ablation (multiphase computed tomography with contrast)",
        "effectiveness of ablation (magnetic resonance imaging)",
        "effectiveness of ablation (ultrasonography not appropriate)"
      ],
      "progression_measures": [
        "progression measures (general)",
        "prognosis (BCLC staging system)",
        "prognosis (Child-Pugh score)",
        "prognosis (MELD score)",
        "prognosis (CLIP score)",
        "prognosis (BCLC staging classification)",
        "portal invasion",
        "extrahepatic spread",
        "histological and prognostic parameters",
        "immunohistochemical confirmation of hepatocytic origin",
        "genetic subtype identification"
      ]
    },
    "safety": {
      "adverse_events": [
        "adverse events (general)",
        "adverse reactions (general)",
        "adverse events (graded by National Cancer Institute)",
        "adverse events (CTCAE v5.0)",
        "adverse events (Grade â‰¥ 3)",
        "serious adverse events",
        "serious adverse reactions (grade 3/4)",
        "serious complications",
        "complications",
        "complication incidence",
        "post-treatment complications",
        "long-term treatment-related complications",
        "side-effects (general)",
        "toxicity",
        "treatment-emergent adverse events (TEAEs)",
        "grade 3 adverse events",
        "grade 4 adverse reactions",
        "grade 5 adverse events",
        "treatment-related deaths",
        "treatment-related mortality",
        "adverse events leading to discontinuation",
        "adverse reactions leading to discontinuation of treatment",
        "drug withdrawal due to adverse events",
        "dose modification due to adverse events",
        "dropout rate for toxicity",
        "serious events",
        "safety",
        "death",
        "secondary cancer",
        "bleeding",
        "haemorrhagic events",
        "brain/gastrointestinal bleeding",
        "brain haemorrhage",
        "haemorrhage",
        "bleeding (EORTC QLQ-HCC18)",
        "rebleeding prophylaxis",
        "perioperative mortality",
        "intraoperative complications",
        "postoperative softening",
        "gallbladder abscess",
        "morbidity",
        "donor morbidity",
        "liver failure",
        "hepatic insufficiency",
        "hepatic encephalopathy",
        "liver disorders",
        "liver-related morbidity",
        "portal vein thrombosis",
        "arterial hypertension",
        "hypertension",
        "hand-foot-skin reaction",
        "hand-foot skin reaction",
        "hand feeding reactions",
        "hand-foot syndrome",
        "skin rash",
        "rash",
        "skin desquamation",
        "desquamation",
        "skin desquamation",
        "dermatitis exfoliative",
        "dry skin",
        "erythema",
        "pruritus",
        "acne",
        "hyperkeratosis",
        "keratoacanthoma",
        "squamous cell cancer of the skin",
        "alopecia",
        "folliculitis",
        "diarrhoea",
        "nausea",
        "vomiting",
        "constipation",
        "abdominal pain",
        "abdominal swelling (EORTC QLQ-HCC18)",
        "pain",
        "pain (EORTC QLQ-HCC18)",
        "back pain",
        "limb pain",
        "joint pain",
        "arthralgia",
        "myalgia",
        "muscle spasms",
        "fatigue",
        "fatigue (EORTC QLQ-HCC18)",
        "hypodynamia",
        "asthenia",
        "weight loss",
        "decreased weight",
        "decreased appetite",
        "anorexia",
        "nutrition",
        "dysphonia",
        "dysgeusia",
        "dyspepsia",
        "dysphagia",
        "stomatitis",
        "mucosal inflammation",
        "gastro oesophageal reflux disease",
        "intestinal failure",
        "infections",
        "sepsis",
        "influenza like illness",
        "infusion reactions",
        "hypersensitivity to monitoring",
        "renal events",
        "renal failure",
        "proteinuria",
        "increased ALT activity",
        "transient increase in transaminases",
        "increased amylase",
        "increased lipase",
        "laboratory haematological testing",
        "laboratory biochemical testing",
        "urinalysis",
        "electrocardiography",
        "QTc prolongation",
        "ALT increase",
        "AST increase",
        "creatinine increase",
        "hypocalcaemia",
        "hypokalaemia",
        "hyponatraemia",
        "hypoglycaemia",
        "hyperthyroidism",
        "hypothyroidism",
        "diabetes mellitus",
        "depression",
        "peripheral sensory neuropathy",
        "tinnitus",
        "neurotoxicity",
        "cough",
        "dyspnoea",
        "shortness of breath",
        "pleural effusion",
        "respiratory failure",
        "flushing",
        "rhinorrhoea",
        "erythema",
        "fever",
        "fever (EORTC QLQ-HCC18)",
        "jaundice (EORTC QLQ-HCC18)",
        "lymphoedema",
        "lymphopenia",
        "leukopenia",
        "neutropenia",
        "anaemia",
        "thrombocytopenia",
        "myocardial infarction",
        "myocardial ischaemia",
        "congestive heart failure",
        "cardiovascular arrest",
        "arterial thromboembolic events",
        "cerebral vascular accident",
        "sudden death",
        "erectile dysfunction"
      ],
      "serious_events": [
        "serious adverse events",
        "serious adverse reactions (grade 3/4)",
        "serious complications",
        "grade 3 adverse events",
        "grade 4 adverse reactions",
        "grade 5 adverse events",
        "treatment-related deaths",
        "treatment-related mortality"
      ],
      "discontinuations": [
        "adverse events leading to discontinuation",
        "adverse reactions leading to discontinuation of treatment",
        "drug withdrawal due to adverse events",
        "dose modification due to adverse events",
        "dropout rate for toxicity"
      ]
    },
    "quality_of_life": {
      "patient_reported_outcomes": [
        "quality of life",
        "health-related quality of life (HRQoL)",
        "global health status (EORTC QLQ-C30)",
        "function scales (EORTC QLQ-C30)",
        "function scales (EORTC QLQ-HCC18)",
        "deterioration in patient quality of life (EORTC QLQ-C30)",
        "deterioration in patient quality of life (EORTC QLQ-HCC18)",
        "EORTC QLQ-C30",
        "EORTC QLQ-HCC18",
        "EORTC QLQ-LC13",
        "EQ-5D",
        "EQ-5D-3L",
        "EQ-5D-5L",
        "EQ VAS (Euro QoL visual analogue scale)",
        "health status (EQ-5D VAS)",
        "FACT-G (Functional Assessment of Cancer Therapy â€“ General)",
        "FACT-Hep",
        "quality of life weights",
        "health state utility values",
        "overall quality of life (measured with a validated and reliable instrument)",
        "FACT-G GP5",
        "visual analogue scale",
        "BPI-SF",
        "FHSI-8 questionnaire",
        "time to clinically meaningful worsening of EQ-5D",
        "time to clinically meaningful worsening of EORTC QLQ-C30 domains",
        "time to clinically meaningful worsening of EORTC QLQ-HCC18 domains"
      ],
      "functional_status": [
        "performance status (ECOG/PS)",
        "Childâ€“Pugh class",
        "albumin-bilirubin (ALBI)",
        "model for end-stage liver disease (MELD)"
      ],
      "symptom_measures": [
        "pain (EORTC QLQ-HCC18)",
        "jaundice (EORTC QLQ-HCC18)",
        "fever (EORTC QLQ-HCC18)",
        "abdominal swelling (EORTC QLQ-HCC18)",
        "fatigue (EORTC QLQ-HCC18)",
        "distress",
        "physical complaints",
        "psychological complaints",
        "psychosocial complaints",
        "general complaints"
      ]
    },
    "economic": {
      "cost_effectiveness": [
        "cost-effectiveness (incremental cost-effectiveness ratio, ICER)",
        "cost-effectiveness analysis",
        "cost-effectiveness",
        "cost per quality-adjusted life year (QALY)",
        "cost-benefit analysis",
        "budget impact"
      ],
      "utilities": [
        "quality-adjusted life years (QALYs)",
        "quality of life weights",
        "health state utility values"
      ],
      "resource_utilization": [
        "length of hospital stay",
        "days of missed work",
        "number needed to harm (NNH)",
        "number needed to treat (NNT)",
        "resource utilization"
      ]
    },
    "other": {
      "exploratory_endpoints": [
        "false positives",
        "early diagnosis",
        "down-staging",
        "donor morbidity",
        "success rate (downstaging/bridging)",
        "bridging therapy benefit (time to progression)"
      ],
      "biomarkers": [
        "blood and tumour biomarkers",
        "alpha-fetoprotein (AFP) monitoring",
        "pharmacokinetics",
        "plasma pharmacokinetics lenvatinib exposure parameters",
        "pharmacodynamic parameters",
        "pharmacodynamics",
        "pharmacokinetic parameters",
        "vital signs"
      ]
    }
  }
}